Step 1 topics → Endocrine → Cushing-Directed Pharmacotherapy

Cushing-Directed Pharmacotherapy

USMLE Step 1 trap: Fails to recognize ketoconazole as an adrenal steroidogenesis inhibitor in Cushing pharmacotherapy. Ketoconazole inhibits multiple cytochrome P450 enzymes including CYP11A1 and CYP11B1, blocking cortisol synthesis and serving as a first-line medical treatment for Cushing syndrome.

Cushing-directed pharmacotherapy covers the drugs used to medically manage hypercortisolism when surgery isn't immediately possible or has failed. The core drugs — ketoconazole, metyrapone, mitotane, mifepristone, pasireotide, and osilodrostat — each work at a distinct point in the cortisol axis, and that specificity is exactly what USMLE Step 1 exploits. Expect questions that give you a clinical scenario (failed transsphenoidal surgery, ectopic ACTH, adrenal carcinoma) and ask you to identify the mechanism or predict a lab finding after starting a specific drug.

What makes this topic genuinely tricky is that it cuts across multiple drug classes that students normally file in completely different categories. Ketoconazole is an antifungal in your pharmacology deck — but on the exam it's an adrenal steroidogenesis inhibitor. Mifepristone is 'the abortion pill' — but here it's a glucocorticoid receptor antagonist, and its unique mechanic (cortisol levels go UP while symptoms improve) is a classic vignette trap. The exam also tests whether you understand upstream vs. downstream: drugs that reduce cortisol production have a different lab signature than drugs that block the receptor.

Passage-based questions may give you a cortisol level and ask why it rose after treatment — that's testing whether you know mifepristone doesn't touch production. Mechanism questions may ask for the specific enzyme target of metyrapone versus ketoconazole versus osilodrostat. USMLE Step 1 rewards students who can link the drug to its enzymatic step, predict the metabolite that accumulates, and distinguish production inhibition from receptor blockade. If you can do all three, you own this topic.

From real student decks
5%have cards covering this topic
3%have mature cards

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake
Wrong: Ketoconazole is only an antifungal and do not recognize it as an adrenal steroidogenesis inhibitor used in Cushing syndrome.
Right: Ketoconazole inhibits multiple cytochrome P450 enzymes including CYP11A1 and CYP11B1, blocking cortisol synthesis and serving as a first-line medical treatment for Cushing syndrome.
Ketoconazole's primary pharmacology course identity as an antifungal (azole class, CYP51 inhibitor for ergosterol synthesis) leads students to mentally file it away and not retrieve it in an endocrine context. But ketoconazole is non-selective — it inhibits human adrenal CYPs including CYP11A1 (cholesterol side-chain cleavage) and CYP11B1 (11-beta-hydroxylase), directly cutting cortisol output. This makes it one of the most commonly used first-line medical therapies for Cushing syndrome, especially while awaiting surgery.
Common mistake
Wrong: Mifepristone treats Cushing syndrome by blocking cortisol synthesis at the adrenal gland.
Right: Mifepristone is a glucocorticoid receptor antagonist that blocks cortisol's peripheral effects without reducing cortisol production, so serum cortisol levels actually rise during treatment.
Mifepristone does not touch the adrenal gland at all — it is a competitive antagonist at the glucocorticoid receptor in peripheral tissues. Because cortisol can't signal normally, the hypothalamic-pituitary axis loses negative feedback and drives ACTH higher, which stimulates more cortisol production. The result is a paradox: the patient's clinical cushingoid features improve, but measured serum cortisol actually rises. This rising cortisol level cannot be used to monitor treatment efficacy, which is another testable point.
Common mistake
Wrong: Pasireotide works by blocking the glucocorticoid receptor at the pituitary.
Right: Pasireotide is a somatostatin analog that binds somatostatin receptors (especially SST5) on corticotroph adenoma cells, suppressing ACTH secretion and thereby reducing cortisol production.
Pasireotide is a somatostatin analog, not a glucocorticoid receptor blocker. Its target is somatostatin receptor subtype 5 (SST5), which is highly expressed on corticotroph adenoma cells in Cushing disease. By binding SST5, it suppresses ACTH secretion directly at the pituitary, reducing downstream cortisol production — the opposite of mifepristone's peripheral mechanism. Think of pasireotide as working 'upstream' (pituitary) while mifepristone works 'downstream' (receptor).
Common mistake
Wrong: Metyrapone blocks the same enzymatic step as aminoglutethimide (cholesterol side-chain cleavage).
Right: Metyrapone specifically inhibits CYP11B1 (11-beta-hydroxylase), the final step converting 11-deoxycortisol to cortisol, causing 11-deoxycortisol to accumulate.
Metyrapone is highly specific: it inhibits CYP11B1, which catalyzes the final hydroxylation step converting 11-deoxycortisol to cortisol. Block this step and 11-deoxycortisol accumulates — a fact the exam uses to test whether you know the drug's target (give the metabolite, ask the drug, or vice versa). Aminoglutethimide acts earlier at cholesterol side-chain cleavage (CYP11A1), the very first committed step; confusing these two means confusing the earliest versus the final enzymatic step in cortisol biosynthesis.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the specific enzyme targets of adrenal steroidogenesis inhibitors: ketoconazole inhibits multiple CYPs (CYP11A1, CYP11B1), metyrapone specifically inhibits CYP11B1 (11-beta-hydroxylase), osilodrostat also inhibits CYP11B1, and mitotane is adrenolytic with broad steroidogenesis suppression — expect questions asking you to match drug to target or predict which precursor accumulates.
  2. Distinguish mifepristone's glucocorticoid receptor antagonism (peripheral blockade, cortisol levels rise) from pasireotide's pituitary-level action as a somatostatin analog that suppresses ACTH secretion from corticotroph adenoma cells — the exam will test whether you can identify the correct mechanism for each and predict the resulting cortisol direction.

Can you avoid these mistakes?

A patient with Cushing disease starts pasireotide. After 2 months, ACTH levels drop significantly. What is the receptor mechanism responsible, and at which anatomical site does this drug act?
A woman with adrenal Cushing syndrome is started on mifepristone. Three weeks later, her moon facies and central obesity are improving, but her serum cortisol level is higher than before treatment. Is this finding expected, and why?
Match each drug to its primary enzymatic target: (a) metyrapone, (b) ketoconazole, (c) osilodrostat. Which metabolite would you expect to accumulate with metyrapone therapy?
A patient with adrenal carcinoma causing Cushing syndrome is treated with a drug that causes adrenolysis and broadly suppresses steroidogenesis. Which drug is this, and how does its mechanism differ from a targeted CYP11B1 inhibitor like metyrapone?

Related topics

Cushing Syndrome (All Causes) Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →